Login / Signup

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

Melinda J GooderhamAndreas PinterL K FerrisR B WarrenTianyu ZhanJ ZengA M SolimanC KaufmannB KaplanH PhotowalaBruce E Strober
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Risankizumab treatment demonstrated high rates of rapid and durable efficacy as measured by absolute PASI thresholds and improvements in patient HRQoL.
Keyphrases
  • coronary artery disease
  • early onset
  • atopic dermatitis